WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

"Nomura: "Buy" rating on WuXi Biologics (02269) with a target price of HK$95.75 https://m.hk.investing.com/news/stock-market-news/article-237383?ampMode=1

CICC: Maintain WuXi Biologics' (02269) "Outperform" rating with a target price of HK$88 https://m.hk.investing.com/news/stock-market-news/article-237332?ampMode=1 China Merchants Securities (Hong Kong): Maintain WuXi Biologics (02269) "Buy" with a target price of HK$171 https://finance.sina.cn/hkstock/ggpj/2022-06-17/detail-imizmscu7268369.d.html?from=wap

M Stanley Lists Top 25 CN/ HK Equities Owned by Active Long-only Managers (Table) http://www.aastocks.com/en/stocks/news/aafn-con/now.1190523/latest-news

https://hk.investing.com/news/stock-market-news/article-236725

"Research Report" Nomura Cuts WuXi Biologics (02269.HK) Target Price to $95.75, Rated "Buy http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1189429/1

WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes https://www.prnewswire.co.uk/news-releases/wuxi-biologics-launches-first-commercial-drug-product-facility-for-pre-filled-syringes-800736778.html • WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-filled syringes (PFS) capacity to 17 million units per year. • WuXi Biologics has established a global manufacturing network with 9 drug product facilities for vial and PFS in China and Germany, and is now one of the global leaders in drug product CDMO services. • Advanced single-use technology and automated equipment allow for decreasing risk of contamination. ...

Harding Loevner - WuXi Biologics: Sporting A 100x Forward Price-To-Earnings Multiple https://seekingalpha.com/article/4515224-wuxi-biologics-sporting-a-100x-forward-price-to-earnings-multiple Summary • We had previously owned WuXi Biologic shares but sold it in the second quarter of 2019. • We bought back WXIBF stock after a sharp price correction in the first quarter of 2021. • The rapid development of several antibody drugs for COVID-19 gave a further, unexpected boost to WuXi’s business recently. • WuXi’s share price tanked despite the positive surprise of an 83% year- over-year increase in revenue growth and a doubling of the company’s adjusted net profits. • Our read of WuXi’s sales growth has, if anything, proven too conservative in the near term, while its execution has been solid. ...

https://finance.sina.cn/hkstock/sckxjfx/2022-05-27/detail-imizmscu3643545.d.html?from=wap

https://finance.sina.cn/hkstock/sckxjfx/2022-05-26/detail-imizirau4855558.d.html?from=wap

http://www.aastocks.com/tc/stocks/news/aafn-con/rum.220526_114143/latest-news

https://www.benzinga.com/news/22/05/27334062/vir-biotechnology-shares-move-lower-co-wuxi-biologics-terminate-a-greater-china-collaboration-agreem

https://finance.sina.cn/hkstock/gsxw/2022-05-16/detail-imcwipik0201838.d.html?from=wap

https://www.defenseworld.net/2022/05/11/wuxi-biologics-cayman-inc-otcmktswxxwy-sees-large-drop-in-short-interest.html

https://finance.sina.cn/hkstock/sckxjfx/2022-05-11/detail-imcwipii9208257.d.html?from=wap

https://tw.stock.yahoo.com/news/%E7%BE%8E%E5%9C%8B%E5%88%B6%E8%A3%81%E4%B8%AD%E4%BC%81%E5%A0%B1%E5%B0%8E%E6%8C%AB%E5%82%B7%E9%A2%A8%E9%9A%AA%E6%83%85%E7%B7%92-%E4%B8%AD%E5%9C%8B-%E8%97%A5%E6%98%8E%E7%B3%BB-%E8%82%A1%E5%83%B9%E9%BD%8A%E8%B7%8C-032743592.html

https://finance.sina.cn/hkstock/sckxjfx/2022-05-05/detail-imcwipii8115898.d.html?from=wap